S

Synaffix BV

33 employees

Synaffix BV creates an antibody conjugation technology platform to aid in the treatment of cancer and other disorders.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Bispecific Antibodies
Health Care
Therapeutics
Antibody-Drug Conjugates (ADCs)
Cell Engagers
Targeted Gene Therapy

Date founded

2014

Funding rounds raised

S

Synaffix BV raised undisclosed on February 18, 2014

Investors: BOM (Brabantse Ontwikkelings Maatschappij), Aravis, BGV (BioGeneration Ventures) and M Ventures

FAQ